Indeed, several targeted nanoparticle formulations are now being tested in clinical trials for cancer treatment, decorated in their surface with antibodies against transferrin receptor, epidermal growth factor receptor, and ephrin type A receptor 2131. This evidence concerns the gene TFRC and cancer.